E-GEOD-51083 - Global gene expression changes in patient-derived CML cell line K562 after short- and long-term BCR-ABL kinase inhibition.

Status
Released on 24 September 2013, last updated on 13 May 2014
Organism
Homo sapiens
Samples (12)
Array (1)
Protocols (7)
Description
K562 cells were treated with the BCR-ABL kinase inhibitor dasatinib over an extended period of time to determine how BCR-ABL inhibition affects BCR-ABL-dependent negative feedback and erythropoietin receptor (EPO-R) signaling. Specifically, what types of changes (upregulation versus downregulation) occur in both the negative and positive regulators of growth-factor receptor signaling. Total RNA was extracted from K562 cells treated with 0.2% DMSO for 24hrs or 100nM dasatinib for 4hrs, 8hrs, and 24hrs.
Experiment type
transcription profiling by array 
Contacts
Neil Shah <geo@ncbi.nlm.nih.gov>, Alma Burlingame, Barry S Taylor, Charles Craik, Cheryl Tajon, Elisabeth A Lasater, Jennifer Gajan, Juan Oses-Prieto, Neil P Shah, Young-wook Jun
MIAME
PlatformsProtocolsFactorsProcessedRaw
Files
Investigation descriptionE-GEOD-51083.idf.txt
Sample and data relationshipE-GEOD-51083.sdrf.txt
Processed data (1)E-GEOD-51083.processed.1.zip
Array designA-GEOD-10558.adf.txt
Links